Antimicrobial resistance

Antimicrobial resistance means that antibiotics are no longer effective to treat an infection. This fact has important implications, since infections caused by resistant bacteria do not respond to first line antibiotics. Resistant infections require of more complex and prolonged treatments, cause higher economic costs, longer hospital stays, sequelae and higher mortality.

Surveillance of antimicrobial resistance is critical to warn about emerging resistance mechanisms, and provides information to guide antimicrobial treatments. In 1996, PAHO/WHO launched the Latin American Surveillance Network of Antimicrobial Resistance (ReLAVRA for its Spanish Acronym), which aims at reporting the magnitude and trends of antimicrobial resistance in the Region, using routine data of microbiology laboratories. The information provided by each National Reference Laboratory (NRL) is collected from sentinel centers. Currently, 21 countries of the Americas report their resistance data annually. The NRL external evaluation program is coordinated by the National Administration of Health Laboratories and Institutes, (ANLIS for its Spanish acronym) "Dr. C. G. Malbrán” in Buenos Aires, Argentina.

From the extensive AMR data available since 2000, a number of pathogens and antibiotics have been selected to be presented in this platform.

Further information available in: http://www.paho.org/antimicrobialresistance

There are no articles in this category. If subcategories display on this page, they may have articles.